Endothelin-1 is an endothelium-derived vasoconstrictor peptide. Its circulating levels are below those known to evoke direct vascular effects. To study whether low concentrations of endothelin-1 potentiate the effects of other vasoconstrictor hormones, we suspended isolated human internal mammary and left anterior descending coronary artery rings in organ chambers for isometric tension recording. In mammary artery rings, the contractions to norepinephrine (3 x 10-8 M) were potentiated by threshold (3 X 10-10 M) and low concentrations (10`M) of endothelin-1 (96±35% and 149±58% increase from control; p<0.01 and 0.001; n=6). The inhibitor of endothelial nitric oxide formation L-NG-monomethyl arginine did not affect the potentiating effects of the peptide. The calcium antagonist darodipine (10`M) prevented the potentiation of the response to norepinephrine evoked by endothelin-1. Similarly, contractions to serotonin (10`or 3 x 10-8 M) were amplified by endothelin-1 (3 x 10-10 M) in the mammary (30±9%o) and in the coronary arteries (59±25%). Endothelin-1 (10-9 M) further potentiated the response (57±23% in mammary and 87±26% in coronary arteries;p <0.05; n=7 and 3). The sensitivity of mammary arteries to calcium chloride was markedly enhanced in the presence of endothelini1 (3 x 1010 M; concentration shift, eightfold; pc<O.O1; n=5). In contrast to endothelin-1, threshold concentrations of serotonin and norepinephrine (10-8 M) did not potentiate contractions induced by endothelin-1 (10-10-10-7 M), nor did serotonin augment the effects of norepinephrine. Thus, in human arteries threshold concentrations of endothelin-1 specifically amplify contractions induced by norepinephrine and serotonin by a calciumdependent mechanism. This may be important in vasospastic syndromes in humans. (Circulation 1990;82:188-195) E ndothelin-1 (human and porcine) is a 21-amino acid peptide that is produced and released by endothelial cells after stimulation with thrombin, transforming growth factor f, adrenalin, phorbol ester, and the calcium ionophore A23187.1-6 In isolated blood vessels of various animal species including humans, the peptide possesses
E ndothelin-1 (human and porcine) is a 21-amino acid peptide that is produced and released by endothelial cells after stimulation with thrombin, transforming growth factor f, adrenalin, phorbol ester, and the calcium ionophore A23187. [1] [2] [3] [4] [5] [6] In isolated blood vessels of various animal species including humans, the peptide possesses potent vasoconstrictor properties that markedly exceed those of other cardiovascular hormones.1'7-'4 Thus, endothelin-1 has been implicated in coronary vasospasm, unstable angina, and hypertension. '5-17 However, measurements of the circulating levels of endothelin-1 in normal subjects by a highly specific and sensitive radioimmunoassay revealed concentrations that are below those inducing significant direct pharmacological effects in isolated blood vessels. '8-20 However, higher levels of the peptide might be present at the level of the vascular smooth muscle.
Low and threshold levels of the peptide could play an important role, if endothelin-1 would sensitize the blood vessel wall to the effects of other vasoconstrictor substances that are found at much higher concentrations than the peptide in the circulating blood or are liberated locally from adrenergic nerves such as norepinephrine21 or released from activated platelets such as serotonin.22-26 Indeed, vasoconstrictor sub-stances can potentiate each other's action on vascular smooth muscle in some,27-32 but not all animal species.33 Thus, the present study was designed to investigate whether threshold concentrations of endothelin-1 can potentiate the effects of norepinephrine and serotonin in human arteries and, if so, what mechanism might be involved.
Methods

Preparation of Blood Vessels
Internal mammary arteries and veins were harvested intraoperatively from patients undergoing coronary bypass surgery for coronary artery disease.9'14,34 Human left anterior descending coronary arteries were obtained from cardiac transplant recipients undergoing transplantation for dilative cardiomyopathy. The blood vessels were dissected free and cleaned of adherent connective tissue under a dissection microscope (Wild and Leitz AG, Zurich, Switzerland).
Solutions
The between each exposure to the hormones was at least 40 minutes. In certain experiments, the arteries were incubated with the dihydropyridine calcium antagonist darodipine (10-7 M) for 10 minutes.36
In another series of experiments, the rings were washed at least twice for 10 minutes with calciumfree control solution containing 2 mM EGTA. After equilibration, the vessels were exposed to calcium free solution containing 100 mM KCI (see "Preparation of Blood Vessels"). A cumulative concentrationresponse curve to calcium chloride (10-7 to 10-3 M) was constructed from data obtained in control rings and in preparations, studied in parallel, that were previously incubated with 3 x 10-10 M of endothelin-1.
Drugs
The following drugs were used: Endothelin-1 (Calbiochem, Lucerne (n=7). L-NMMA, however, did not alter the potentiation of the contraction to norepinephrine evoked by endothelin-1 (3 x 10-10 M; Table 1 ). Threshold concentrations of norepinephrine (10 8 M), which by themselves evoked only a small increase in tension (0.2±+0.1 g), did not significantly affect the half-maximal (pD2 value) nor the maximal contraction induced by endothelin-1 (10-10 to 10-7 M; Table 2 ).
In contrast to the internal mammary artery, the contractions induced by norepinephrine (10-8 M) were not augmented in the presence of endothelin-1 (10-11 to 10-9 M) in the human internal mammary vein (n=6; data not shown).
Endothelin-1 and Serotonin
In isolated internal mammary arteries with endothelium, serotonin (10-7 M) induced an increase in In internal mammary arteries, threshold concentrations of serotonin (10-8 M) , which by themselves induced a small increase in tension (0.3+±0.1 g), did not augment the contractions elicited by endothelin-1 (10-10 to 10`M; Table 2 ).
Norepinephrine and Serotonin
In certain experiments, a possible interaction between norepinephrine and serotonin was studied. p<0.05 vs. the response to norepinephrine in the presence of endothelin-1 10-9 M, but not significant vs. the control response to norepinephrine). Discussion The present study demonstrates that in the human internal mammary artery threshold concentrations of endothelin-1 potentiate the vasoconstrictor effects of norepinephrine and serotonin. Because endothelin-1 sensitized the vascular smooth muscle of the human arteries to extracellular calcium and because the calcium antagonist darodipine prevented the potentiating effects of the peptide, a calcium-dependent mechanism must be involved.
An amplification of the effects of vasoconstrictor substances by low concentrations of other hormones and autacoids has been described for serotonin in the caudal artery and in the perfused kidney of the rat29,3' and in the ear and femoral artery of the rabbit.28,30 In the canine femoral artery, however, no significant interaction between a-adrenergic and serotonergic receptors has been noted,33 indicating that amplification responses depend on the species and blood vessels studied and the agonists used. This study demonstrates that endothelin-1 potentiates contractions induced by norepinephrine37,38 and serotonin in human arteries. Unlike the femoral artery of the rabbit where most agonists can augment each other's action,30 the potentiating effects of endothelin-1 in the human internal mammary artery were specific for the peptide, because low concentrations of serotonin did not augment contractions induced by either norepinephrine or endothelin-1 and because threshold concentrations of norepinephrine did not potentiate the contractions evoked by the peptide.
The endothelial layer not only produces endothelin-1,1-6 but also endothelium-derived nitric oxide, which is a potent vasodilator.39,40 The production of endothelium-derived nitric oxide from L-arginine can be inhibited by a methylated form of the amino acid L-NMMA.354' In human arteries, endotheliumderived nitric oxide must be continuously formed, because L-NMMA evoked endothelium-dependent contractions as it has been reported in arteries of experimental animals. 35 Inhibition of the endothelial L-arginine pathway with L-NMMA, however, did not augment the potentiating effects of endothelin-1 on the contractions induced by norepinephrine. In line with this observation in the human internal mammary artery, endothelial removal only minimally enhances the direct contractile effects of endothelin-1 at high concentrations of the peptide. However, darodipine prevented the potentiation of the response to norepinephrine by endothelin-1, indicating that influx of extracellular calcium through voltage-operated calcium channels importantly contributes to the potentiating effects of the peptide. Indeed, endothelin-1 markedly augmented the sensitivity of depolarized vascular smooth muscle to extracellular calcium. Thus, the indirect (potentiating) vascular effects of endothelin-1 may involve activation of voltage-operated calcium channels, as it has been proposed in the porcine coronary artery.47 In addition, the peptide releases calcium from intracellular stores48 and in turn may reduce the buffering effects of the superficial sarcoplasmic reticulum49 during influx of extracellular calcium.
Activation of voltage-operated calcium channels may occur either directly (after activation of the endothelin-1 receptor, most likely involving a G protein linked to the channels47) or indirectly through changes in membrane potential evoked by an agonist (involving nonspecific ion channels50). In canine veins, the depolarization induced by endothelin-1 occurs at lower concentrations than in arteries.50 Because membrane potential of the human arteries was not measured in this study, a contribution of this vascular action of endothelin-1 to its potentiating effects cannot be excluded. However, the fact that changes in membrane potential have been reported at much higher concentrations50 than those required to potentiate the contractions induced by norepinephrine or serotonin in human arteries argues against this hypothesis. Indeed, if changes in membrane potential would mediate these effects, one would expect a more pronounced response in veins than in arteries. However, in contrast to human arteries, the potentiating effects of endothelin-1 could not be demonstrated in human veins (i.e., human internal mammary vein). Thus, the potentiating effects of endothelin-1 in human arteries most likely involve direct activation of voltage-operated calcium channels. 47 The amplifying effects of endothelin-1 may have important clinical implications. Thus, even slight elevations of circulating (as demonstrated in the coronary sinus of patients with coronary artery disease51) and particularly local endothelin-1 concentrations at the level of the smooth muscle may profoundly affect vascular tone and in turn local blood flow. In cultured endothelial cells and the intact porcine aorta,l-6 the formation and secretion of the peptide can be stimulated by thrombin, and in the former, formation and secretion can be stimulated by tumor-transforming factor P3 and epinephrine. In unstable angina and myocardial infarction, local platelet activation occurs.1752-55 Thus, at sites where platelets are activated, thrombin, which is formed after activation of the coagulation cascade,55 and tumor transforming factor ,B, which is released from platelets,56 are abundantly present and would stimulate the formation of the peptide.2,5,6 Serotonin is also released from platelets under these conditions,1722-26,57 and its vasoconstrictor action is amplified by endothelin-1. This may be particularly important, because, in contrast to dog and pig arteries,22-25,58 the monoamine does not induce endothelium-dependent relaxation in human coronary and internal mammary arteries.59,60 Thus, endothelin-1 may importantly contribute to vascular mechanisms involved in acute ischemic syndromes associated with platelet activation.61,62
The human coronary artery63M4 and the internal mammary artery can undergo spasm, which is a clinically relevant problem immediately after coronary bypass surgery. 65 In the pig coronary artery, endothelial damage and regeneration are associated with endothelium dysfunction58 and vasospasm.66 Similar changes may occur in certain arterial bypass grafts after surgical handling. If endothelin-1 were produced by functionally altered endothelial cells, it can contribute to the development of vasospasm, particularly if the sympathetic nervous system or platelets are activated.2538 Indeed, in the human coronary circulation, ergonovine, which activates serotonergic receptors, is the most reliable substance to provoke vasospasm in patients with variant angina.67
